Japanese drugmaker Eisai (TYO: 4523) said yesterday that it has received a favorable decision regarding the lawsuit filed in ...

Shilpa Medicare failed to prove invalidity of patent covering Lenvima | Eisai says ruling keeps India-based generic maker’s ...

The verdict of the US district court in New Jersey is that Shilpa's generic infringes a US patent on multikinase inhibitor ...

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other ...

Japanese drugmaker Eisai (TYO: 4523) today announced that the in-house-discovered and developed orexin receptor antagonist ...